Hyloris Developmentsen Sa - Asset Resilience Ratio
Hyloris Developmentsen Sa (HYL) has an Asset Resilience Ratio of 1.36% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Hyloris Developmentsen Sa's Asset Resilience Ratio has changed over time. Check Hyloris Developmentsen Sa strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Hyloris Developmentsen Sa's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see HYL market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €505.00K | 1.36% |
| Total Liquid Assets | €505.00K | 1.36% |
Asset Resilience Insights
- Limited Liquidity: Hyloris Developmentsen Sa maintains only 1.36% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hyloris Developmentsen Sa Industry Peers by Asset Resilience Ratio
Compare Hyloris Developmentsen Sa's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX |
Biotechnology | 46.79% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 63.47% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Hyloris Developmentsen Sa (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Hyloris Developmentsen Sa.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 1.35% | €556.00K ≈ $650.02K |
€41.34 Million ≈ $48.32 Million |
+0.30pp |
| 2023-12-31 | 1.05% | €499.00K ≈ $583.38K |
€47.68 Million ≈ $55.74 Million |
-15.12pp |
| 2022-12-31 | 16.16% | €10.00 Million ≈ $11.69 Million |
€61.86 Million ≈ $72.33 Million |
+15.33pp |
| 2021-12-31 | 0.83% | €528.00K ≈ $617.29K |
€63.44 Million ≈ $74.17 Million |
+0.82pp |
| 2020-12-31 | 0.01% | €7.00K ≈ $8.18K |
€69.18 Million ≈ $80.88 Million |
-0.22pp |
| 2017-12-31 | 0.23% | €10.00K ≈ $11.69K |
€4.37 Million ≈ $5.10 Million |
-0.74pp |
| 2016-12-31 | 0.97% | €13.00K ≈ $15.20K |
€1.34 Million ≈ $1.57 Million |
-- |
About Hyloris Developmentsen Sa
Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen used for post-operative pain, the opioid crisis, and acute pain; Podofilox Gel, an antimycotic drug for the treatment of external genital and perianal warts caused by various types of the h… Read more